In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.41 below Vaxart Inc average.

Within Biotechnology & Pharmaceuticals industry 112 other companies have achieved higher Quick Ratio than Vaxart Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1921, from total ranking in the second quarter 2026 at 3027.

Explain Quick Ratio?
How much Cash & cash equivalents VXRT�s has?
What are VXRT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VXRT/financial-strength

https://api.csimarket.com/api/v1/companies/VXRT/fundamentals

https://api.csimarket.com/api/v1/companies/VXRT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

VXRT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-56.33 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	155.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.41	Subscribe	Subscribe	Subscribe	Subscribe
VXRT's Total Ranking	# 1921	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	1.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-60.5 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 113
Healthcare Sector	# 617
Overall Market	# 1921

Quick Ratio Statistics
High	Average	Low
26.24	4.4	0.05
(Mar 31 2012)		(Jun 30 2025)

Financial Statements
Vaxart Inc 's Current Liabilities	$ 74 Millions	Visit VXRT's Balance sheet
Vaxart Inc 's Cash & cash equivalent	$ 30 Millions	Visit VXRT's Balance sheet
Source of VXRT's Sales		Visit VXRT's Sales by Geography

Cumulative Vaxart Inc 's Quick Ratio

VXRT's Quick Ratio for the trailling 12 Months

VXRT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-34.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	121.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.41	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2223	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-23.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	16.96 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to VXRT Financial Strength Comparisons >> Go to Compare VXRT Quick Ratio to its Competitors

On the trailing twelve months basis VXRT Cash & cash equivalent more than doubled by 155.48 % in Q3 2026 year on year, while Current Liabilities rose to $74 millions, this led to increase in in Vaxart Inc 's Quick Ratio to 0.41, Quick Ratio remained below VXRT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Vaxart Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3991 to 4035.

Explain Quick Ratio?
How much Cash & cash equivalents VXRT�s has?
What are VXRT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 903
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
17.86	4.84	0.31
(Sep 30 2012)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Metagenomi Therapeutics Inc	1.12	$ 36.107 Millions	$ 32.340 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Coherus Oncology inc	1.11	$ 83.629 Millions	$ 75.636 Millions
Biocardia Inc	1.06	$ 2.224 Millions	$ 2.092 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Passage Bio Inc	0.97	$ 20.160 Millions	$ 20.743 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
Mink Therapeutics Inc	0.91	$ 7.471 Millions	$ 8.175 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Protalix Biotherapeutics inc	0.73	$ 22.035 Millions	$ 30.233 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions
Pelthos Therapeutics Inc	0.57	$ 17.921 Millions	$ 31.435 Millions
Iovance Biotherapeutics inc	0.55	$ 57.934 Millions	$ 105.774 Millions
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Surrozen Inc	0.35	$ 100.353 Millions	$ 286.684 Millions
Pluri Inc	0.23	$ 7.678 Millions	$ 32.830 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions

Date modified: 2026-11-06T09:29:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.